Publication:
Active site binding modes of HIV-1 reverse transcriptase inhibitors from natural products

dc.contributor.authorWeerasak Sameeen
dc.contributor.authorJiraporn Ungwitayatornen
dc.contributor.authorวีระศักดิ์ สามี
dc.contributor.authorจิรภรณ์ อังวิทยาธร
dc.contributor.otherSrinakharinwirot University. Faculty of Pharmacy. Department of Pharmaceutical Chemistry and Pharmacognosy.
dc.contributor.otherMahidol University. Faculty of Pharmacy. Department of Pharmaceutical Chemistry.
dc.date.accessioned2010-08-16T06:37:49Zen
dc.date.accessioned2011-08-29T10:41:55Z
dc.date.accessioned2021-05-17T15:35:58Z
dc.date.available2010-08-16T06:37:49Zen
dc.date.available2011-08-29T10:41:55Z
dc.date.available2021-05-17T15:35:58Z
dc.date.created2010-08-16T06:37:49Zen
dc.date.issued2003en
dc.description.abstractUsing the crystal structure of the complex of. HIV-1 reverse transcriptase catalytic core domain with an inhibitor bound to the active site, structural models for the interaction of various natural products with HIV-1 reverse transcriptase were generated by computational docking. The ligands from natural products and nevirapine are found to bind preferably in similar ways at active site. The binding site is formed by residues 100-103, 106, 181, 188, 227, 229, 234 and 235. The coherent picture of possible interactions of natural products at the active site provides an improved basis for structure-based ligand design. The hydrophobic interaction at the hydrophobic pocket, hydrogen bond interaction with the Lys103 and 101 and the angle between systems of ligand which should be in the range of 108-115° are suggested to be of prime importance. Although, costatolide and 4' ,6'-dihydroxyavarone are not able to form hydrogen bonds with Lys103, they do show tight binding with HIV-1 reverse transcriptase enzyme. Therefore, in the situation that Lys103 is mutated which usually occurs during treatment with nevirapine, costatolide and 4',6' -dihydroxyavarone are still effective. This leads to the further development of these two compounds as" non-nucleoside reverse transcriptase inhibitors (NNRTls) for the treatment of the nevirapine-resistant HIV-1 strains.
dc.format.extent4.45 mben
dc.format.mimetypeapplication/pdfen
dc.identifier.citationSrinakharinwirot Journal of Pharmaceutical Sciences. Vol. 8, No.1 (2003),10-24.
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/62207
dc.language.isoengen
dc.rightsMahidol Universityen
dc.rights.holderSrinakharinwirot University
dc.sourceSrinakharinwirot Journal of Pharmaceutical Sciences
dc.subjectHIV-1 reverse transcriptase inhibitorsen
dc.subjectBinding Modesen
dc.subjectNatural products
dc.titleActive site binding modes of HIV-1 reverse transcriptase inhibitors from natural productsen
dc.typeResearch Articleen
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
py-ar-jiraporn-2003.pdf
Size:
4.46 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:

Collections